Clinical Trial Update: Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected [Phase 3]

View source ↗

Summary

A Phase 3 trial of alpelisib plus olaparib for platinum-resistant/refractory high-grade serous ovarian cancer without germline BRCA mutations has been terminate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Serous Ovarian Cancer
• Ovarian Cancer

Drugs mentioned

• Alpelisib (alpelisib)
• Olaparib (Olaparib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Ovarian Cancer | Phase 3 | Status: TERMINATED